logo

Supernus Pharmaceuticals, Inc. (SUPN)



Trade SUPN now with
  Date
  Headline
5/2/2022 8:32:38 AM Supernus: FDA Approves Expanded Indication For Qelbree For Treatment Of Attention Deficit Hyperactivity Disorder
12/8/2021 8:49:08 AM Supernus Resubmits NDA For SPN-830 Apomorphine Infusion Device For Treatment Of Motor Fluctuations In PD
10/11/2021 6:35:55 AM Supernus To Acquire Adamas Through Tender Offer For $8.10/Shr Cash
11/11/2014 5:32:53 PM Supernus Pharmaceuticals, Inc. (SUPN) Has Raised Its FY14 Revenue Estimate To $115 - $118 Mln From $105 Mln